Valuation : FunPep Company Limited

Market Cap 2.74B 17.82M 15.33M 14.43M 13.15M 24.61M 1.7B 24.71M 171M 66.12M 864M 66.9M 65.44M P/E 2024
-4.22x
P/E 2025 -1.63x
Enterprise Value 968M 6.3M 5.42M 5.11M 4.65M 8.71M 600M 8.74M 60.53M 23.39M 306M 23.67M 23.15M EV / Sales 2024
338x
EV / Sales 2025 -
Free-Float
81.08%
Yield 2024 *
-
Yield 2025 -
03-08 FunPep Company Limited announced that it has received ¥32.5315 million in funding from Next Growth Co., Ltd., Growth Capital, Inc. CI
02-19 FunPep Company Limited announced that it expects to receive ¥32.5315 million in funding from Next Growth Co., Ltd., Growth Capital, Inc. CI
09/03/25 FunPep Company Limited announced that it has received ¥3.6 million in funding from SBI Securities Co., Ltd. CI
20/02/25 FunPep Company Limited announced that it expects to receive ¥3.6 million in funding from SBI Securities Co., Ltd. CI
21/07/24 FunPep Company Limited announced that it has received ¥3.52 million in funding from SBI SECURITIES Co., Ltd. CI
04/07/24 FunPep Company Limited announced that it expects to receive ¥3.52 million in funding from SBI SECURITIES Co., Ltd. CI
20/03/24 FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
03/03/24 FunPep Company Limited announced that it expects to receive ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
14/11/23 FunPep Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
15/05/23 FunPep Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
30/09/22 FunPep Company Limited completed the acquisition of Anti-Aging Peptide Co., Ltd. from Hironori Nakagami , Bio Site Start Fund L.P., Naotaka Hashiya, Chiyako Ueda, ReBeage Co., Ltd. and others. CI
13/07/22 FunPep Company Limited agreed to acquire Anti-Aging Peptide Co., Ltd. from Hironori Nakagami , Bio Site Start Fund L.P., Naotaka Hashiya, Chiyako Ueda, ReBeage Co., Ltd. and others. CI
12/12/21 FunPep Company Limited announced that it has received ¥3.741 million in funding from SBI Securities Co., Ltd., Investment Arm CI
1 day+1.89%
1 week+3.85%
Current month+1.89%
1 month+10.20%
3 months-6.90%
6 months-51.79%
Current year-34.15%
1 week 50
Extreme 50
54
1 month 48
Extreme 48
54
Current year 45
Extreme 45
130
1 year 45
Extreme 45
130
3 years 45
Extreme 45
325
5 years 45
Extreme 45
477
10 years 45
Extreme 45
843
Manager TitleAgeSince
Director of Finance/CFO 53 30/04/2015
President 62 31/12/2019
Chief Tech/Sci/R&D Officer 55 30/06/2015
Director TitleAgeSince
Chairman 78 28/02/2015
Director/Board Member 62 28/02/2015
Director/Board Member 55 30/11/2015
Date Insider Type Main position Quantity % Market Cap. Importance
28/04/25
Sola KK
OthersCompany 30,000 0.0926%
28/04/25
Sola KK
OthersCompany 50,000 0.1543%
28/04/25 Others 40,000 0.1234%
Change 5-day change 1-year change 3-year change Capi.($)
+1.89%+3.85%-54.24%-67.86% 17.41M
-3.24%-7.78%-5.35%+10.43% 48.01B
+1.06%+0.22%+412.19%+537.94% 44.44B
-1.31%-3.33%+34.50%+18.45% 42.67B
-0.49%-3.21%-0.28%+67.34% 39.96B
0.00%-2.61%+13.09%+42.33% 32.75B
-2.38%-1.36% - - 17.74B
-1.59%-2.05%+19.62%+107.93% 16.49B
-0.37%-2.53%+10.91%+30.93% 14.38B
-1.07%-5.00%+76.11%+38.82% 13.4B
Average -0.69%-0.28%+56.28%+87.37% 26.99B
Weighted average by Cap. -0.91%-1.10%+85.07%+126.98%

Financials

2024 2025
Net sales 6M 39.07K 33.62K 31.65K 28.84K 53.97K 3.72M 54.18K 375K 145K 1.89M 147K 144K -
Net income -889M -5.79M -4.98M -4.69M -4.27M -8M -551M -8.03M -55.59M -21.48M -281M -21.74M -21.26M -1.91B -12.44M -10.71M -10.08M -9.19M -17.19M -1.18B -17.26M -119M -46.18M -603M -46.72M -45.71M
Net Debt -2.35B -15.28M -13.14M -12.38M -11.28M -21.1M -1.45B -21.18M -147M -56.69M -741M -57.36M -56.11M -1.77B -11.51M -9.91M -9.33M -8.5M -15.9M -1.1B -15.97M -111M -42.73M -558M -43.23M -42.29M
Logo FunPep Company Limited
FunPep Co Ltd is a Japan-based company engaged in the research and development business for pharmaceuticals. The main business is to promote research and development of functional peptides, which are the results of research at the Graduate School of Medicine, Osaka University, and to put them into practical use in the business fields such as pharmaceuticals, cosmetics and medical devices. The business model defines its technical area as a functional peptide-based area and a related area that has synergies with it. The Research & Development pipeline is composed of research themes for antibody-inducing peptides and developed products. The Company is engaged in the sale of peptide active ingredients through cosmetic raw material trading companies or sales companies.
Employees
-
Date Price Change Volume
09/09/26 JP¥54.00 +1.89% 143,700
08/09/26 JP¥53.00 +3.92% 367,900
07/09/26 JP¥51.00 0.00% 86,300
04/09/26 JP¥51.00 +2.00% 90,500
03/09/26 JP¥50.00 0.00% 40,200

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4881 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!